Last updated: February 24, 2026
What is the currently approved indication and formulation?
NDC 00904-6084 refers to Oxycodone Hydrochloride Extended-Release (ER), indicated for management of pain severe enough to require continuous, long-term opioid treatment and for which alternative treatments are inadequate. The formulation is extended-release oral tablets.
Market size and demand dynamics
Industry overview
The opioid analgesic market, valued at approximately $12 billion globally in 2022, primarily depends on drug classes such as oxycodone, hydrocodone, and fentanyl. The U.S. accounts for more than 70% of sales, driven by chronic pain management needs.
Market drivers
- Chronic pain prevalence: Estimated at 20% of American adults experience chronic pain, increasing demand.
- Prescription trends: An increase in long-term opioid prescriptions prior to recent regulatory tightening.
- Regulatory environment: Stricter controls implemented from 2018 onward have driven competition toward abuse-deterrent formulations and alternative pain management therapies.
Key competitors
| Product Name |
Market Share (2022) |
Notable Features |
| OxyContin (Purdue Pharma) |
28% |
Extended-release, abuse-deterrent |
| Xtampza ER (Collegium) |
12% |
Abuse-deterrent, flexible dosing |
| Percocet (AbbVie) |
9% |
Combination with acetaminophen |
| Generic oxycodone ER |
32% of total market |
Cost competitiveness |
Regulatory impacts
The Drug Enforcement Agency (DEA) and FDA introduced 2018 measures promoting abuse-deterrent formulations. This shifted market share toward branded abuse-deterrent products and generics with abuse-deterrent properties.
Pricing factors
- Brand vs. generic: Generic oxycodone ER formulations are priced 20-40% lower than branded products.
- Pricing trends: Average wholesale acquisition cost (WAC) for branded oxycodone ER was approximately $7 per tablet in 2022, while generics stood around $4.
- Reimbursement: Medicare and Medicaid influence pricing, with ongoing policy focus on reducing opioid overprescription.
Price projections and market forecasts
Short-term outlook (2023-2025)
Estimated CAGR of 3-5% in the oxycodone ER market, driven by sustained demand, while regulatory pressures continue to influence pricing.
| Year |
Average Wholesale Price per Tablet |
Commentary |
| 2023 |
$4.20 |
Slight increase due to inflation and demand stability |
| 2024 |
$4.40 |
Slight price inflation, potential for increased generic competition |
| 2025 |
$4.60 |
Market stabilizes with marginal growth |
Long-term outlook (2026-2030)
Market growth is expected to plateau as policies further restrict opioid prescriptions and alternative therapies expand. Estimated CAGR over this period drops to 1-2%.
| Year |
Average Wholesale Price per Tablet |
Commentary |
| 2026 |
$4.70 |
Market saturation increases |
| 2028 |
$4.85 |
Adoption of abuse-deterrent generics persists |
| 2030 |
$5.00 |
Slight growth driven by inflation and treatment needs |
Revenue implications
Assuming annual sales volume of 200 million tablets, the product could generate approximately $820 million in 2023, increasing modestly over the coming years with stabilized demand and pricing.
Key market concerns influencing future pricing
- Opioid regulation: Stricter prescribing limits and increased enforcement could reduce volume.
- Developments in pain management: Alternative therapies, including non-opioid medications and interventional procedures, could suppress long-term demand.
- Legal and liability risks: Ongoing litigation and FDA scrutiny could influence manufacturer pricing strategies.
Key Takeaways
- The market for oxycodone ER drugs like NDC 00904-6084 remains significant but is constrained by regulatory pressure and shifts to abuse-deterrent formulations.
- Pricing in the U.S. sees a slight upward trend driven by inflation and demand stabilization, with branded products priced significantly higher than generics.
- Market growth is moderate; long-term projections suggest stabilization as alternative therapies expand and regulations tighten.
- Revenue projections reflect continued demand, with sales influenced heavily by policy and legal risks.
- Future pricing depends on the interplay of regulatory changes, market share shifts toward abuse-deterrent and generic formulations, and evolving pain management practices.
FAQs
Q1: How does regulatory pressure affect the market for oxycodone ER drugs?
Regulatory changes limit prescriptions, encourage abuse-deterrent formulations, and promote alternative therapies, all of which influence demand and pricing.
Q2: What is the typical price difference between branded and generic oxycodone ER?
Brand-name products typically cost 40% more than generics, with prices around $7 vs. $4 per tablet in 2022.
Q3: Are there upcoming patent expirations or exclusivity periods for NDC 00904-6084?
The exact patent expiration date depends on the manufacturer; for recent formulations, exclusivity may extend until 2028-2030, after which generics will dominate.
Q4: How might non-opioid pain treatments impact the oxycodone ER market?
Innovations in non-opioid pain management could reduce long-term demand for oxycodone ER, capping market growth.
Q5: What are the primary legal risks for manufacturers of oxycodone ER formulations?
Litigation related to opioid misuse and overprescription has led to multibillion-dollar settlements, pressuring pricing strategies and market stability.
References
- U.S. Food and Drug Administration. (2022). Opioid analgesic approval and regulation updates.
- IQVIA Institute. (2022). The Prescription Drug Market and Revenue Trends.
- DEA. (2018). Regulatory measures and opioid prescription guidelines.
- MarketWatch. (2022). Global opioids market size and forecasts.
- MedPage Today. (2023). Impact of regulations on opioid pricing and market dynamics.
Note: The data presented above reflects estimates and projections based on current market conditions as of 2023 and may evolve with future regulatory, legal, and technological developments.
